We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

73 hedge funds and large institutions have $129M invested in Invesco Biotechnology & Genome ETF in 2014 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 7

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

40% more capital invested

Capital invested by funds: $92.6M → $129M (+$36.7M)

22% more funds holding

Funds holding: 60 → 73 (+13)

1.41% less ownership

Funds ownership: 32.49% → 31.08% (-1.4%)

Holders
73
Holders Change
+13
Holders Change %
+21.67%
% of All Funds
2.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
25
Reduced
12
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$4.41M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$4.23M
3
U
UBS
Switzerland
+$3.41M
4
HighTower Advisors
HighTower Advisors
Illinois
+$3.31M
5
VKH
Virtu KCG Holdings
New York
+$2.7M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$6.87M
2
FAAS
First Allied Advisory Services
California
-$632K
3
PFG
Pacific Financial Group
Washington
-$274K
4
Invesco
Invesco
Georgia
-$259K
5
B
Baird
Wisconsin
-$210K
Name Holding Trade Value Shares
Change 		Change in
Stake
Verition Fund Management
26
Verition Fund Management
Connecticut
$901K +$926K +21,639 New
WBG
27
Wharton Business Group
Pennsylvania
$894K -$177K -4,132 -16%
Citadel Advisors
28
Citadel Advisors
Florida
$876K +$900K +21,039 New
Goldman Sachs
29
Goldman Sachs
New York
$862K +$445K +10,411 +101%
CWM
30
Concert Wealth Management
California
$789K +$839K +19,607 New
OPCM
31
Osborne Partners Capital Management
California
$777K -$3.42K -80 -0.4%
LTFS
32
Ladenburg Thalmann Financial Services
Florida
$561K -$2.91K -68 -0.5%
Deutsche Bank
33
Deutsche Bank
Germany
$511K +$92.2K +2,154 +21%
BPC
34
Banque Pictet & Cie
Switzerland
$491K +$504K +11,790 New
Janney Montgomery Scott
35
Janney Montgomery Scott
Pennsylvania
$411K +$101K +2,362 +31%
SB
36
Suntrust Banks
Georgia
$397K +$108K +2,523 +36%
TT
37
Tower Trust
Indiana
$339K – – –
AP
38
Advisors Preferred
Maryland
$331K +$178K +4,161 +109%
CAN
39
Cetera Advisor Networks
California
$316K +$95.8K +2,240 +41%
Citigroup
40
Citigroup
New York
$290K +$155K +3,630 +109%
PJSIMP
41
P.J. Schmidt Investment Management (PJS)
Wisconsin
$289K – – –
JIC
42
Joel Isaacson & Co
New York
$287K +$295K +6,890 New
OIA
43
Optimum Investment Advisors
Illinois
$286K +$199K +4,640 +209%
CIC
44
Carnegie Investment Counsel
Ohio
$283K -$2.14K -50 -0.7%
Cambridge Investment Research Advisors
45
Cambridge Investment Research Advisors
Iowa
$280K +$288K +6,729 New
MAA
46
Managed Account Advisors
New Jersey
$272K +$71K +1,659 +34%
NPC
47
National Planning Corporation
California
$247K +$249K +5,816 New
OC
48
Oppenheimer & Co
New York
$242K -$9.67K -226 -4%
MCM
49
Murphy Capital Management
New Jersey
$217K +$223K +5,220 New
WA
50
WBH Advisory
Maryland
$214K +$220K +5,151 New
1
2
3 4

PBE Hedge Fund Activity: Q1 2014 in Review

73 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2014, worth a combined $129M — up 40% from $92.6M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PBE positions and 7 closed out — a net gain of 13 holders — while 25 added to existing stakes and 12 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $4.41M. The largest seller was Morgan Stanley, cutting an estimated $6.87M.

  • 73 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2014, up from 60 in Q4 2013.
  • Funds reported $129M of Invesco Biotechnology & Genome ETF stock for Q1 2014, up 40% quarter-over-quarter.
  • 20 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2014 and 7 closed out, a net change of +13 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q1 2014 was Jane Street, an estimated $4.41M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q1 2014 was Morgan Stanley, an estimated $6.87M sold.

Based on aggregated 13F filings for Q1 2014.